TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23131570

Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil (SBO) extract, 4 capsules per day, each containing 500 mg, for 8 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo, 4 capsules per day for 8 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil (SBO) extract
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 22283033

Group type: EXPERIMENTAL
Intervention: Zinc (5 mg), Iron (6.25 mg), Folic Acid (25 microg) supplementation
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Combined micronutrient supplements (Zinc, Iron, Folic Acid)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study: 20128376

Group type: EXPERIMENTAL
Intervention: valsartan/amlodipine 80/5 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: monotherapy (amlodipine 5 mg or valsartan 80 mg)
Number of subjects: 0
Study: 16401691

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg for three weeks, 40 mg for three weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 15230994

Group type: EXPERIMENTAL
Intervention: High beta-carotene concentration
Number of subjects: 652

Group type: COMPARATOR
Intervention: Low beta-carotene concentration
Number of subjects: 652

Group type: COMPARATOR
Intervention: alpha-Carotene, beta-cryptoxanthin, lycopene, lutein, zeaxanthin
Number of subjects: 652
Study: 10894590

Group type: EXPERIMENTAL
Intervention: 24 weeks of ribavirin/interferon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 48 weeks of ribavirin/interferon
Number of subjects: 0

Group type: COMPARATOR
Intervention: 48 weeks of interferon alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 24 weeks of combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 48 weeks of combination therapy
Number of subjects: 0
Study: 9004394

Group type: EXPERIMENTAL
Intervention: Treatment effect estimate under covariate omission or categorization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correct adjustment of treatment effect estimate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Covariate omission or categorization
Number of subjects: 0
Study: 7801569

Group type: EXPERIMENTAL
Intervention: Specified formula for assessing the volume of the right ventricular outlet section
Number of subjects: 0

Group type: COMPARATOR
Intervention: Main formula for assessing the volume of the right ventricular outlet section
Number of subjects: 0
Study: 6279142

Group type: EXPERIMENTAL
Intervention: Single massive dose of 15 mg vitamin D orally
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Daily supplementation of 50 micrograms vitamin D for 20 days
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normal children (control group)
Number of subjects: 37
Study: 31343205

Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 155
Study: 30829516

Group type: EXPERIMENTAL
Intervention: Telephone feedback intervention
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Letter feedback intervention
Number of subjects: 1003

Group type: COMPARATOR
Intervention: No-contact control condition
Number of subjects: 1003
Study: 27867020

Group type: EXPERIMENTAL
Intervention: PO baclofen 20 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IV baclofen 15 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: PO baclofen (10 mg, 15 mg, 20 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: IV baclofen (7.5 mg, 11.5 mg, 15 mg)
Number of subjects: 36
Study: 26549276

Group type: EXPERIMENTAL
Intervention: New-generation diabetes-specific formula (Group A)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control diabetes-specific formula (Group C)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Both diabetes-specific formulas (Group A and Group C)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Standard control formula (Group B)
Number of subjects: 157
Study: 23345946

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed guar gum (PHGG) at dosage of 5 g/d (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (fruit-juice, n = 30)
Number of subjects: 60
Study: 21795652

Group type: EXPERIMENTAL
Intervention: Guided self-help (GSH) plus usual care (UC)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 127
Study: 19299778

Group type: EXPERIMENTAL
Intervention: Oral 5 mg melatonin
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 17535013

Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Higher surgical trainees performing operations
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Duration of operation and complication rate
Number of subjects: 209
Study: 16169530

Group type: EXPERIMENTAL
Intervention: Bipolar I disorder subjects (BP-I)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 8
Study: 14504664

Group type: EXPERIMENTAL
Intervention: Bambuterol (10 mg tablets twice daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Terbutaline (7.5 mg controlled release tablets twice daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous terbutaline (injected intradermally)
Number of subjects: 10
Study: 10490735

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide (Pnc PS) vaccine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hib-diphtheria toxoid conjugate vaccine (PRP-D)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide (Pnc PS) and Hib-diphtheria toxoid conjugate vaccine (PRP-D)
Number of subjects: 20
Study: 8520793

Group type: EXPERIMENTAL
Intervention: Furosemide aerosol (10 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Furosemide aerosol (10 mg four times per day) for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Furosemide treatment over 1 month
Number of subjects: 24
Study: 1787680

Group type: EXPERIMENTAL
Intervention: Intravascular laser irradiation of blood
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard chemotherapy (Control)
Number of subjects: 72
Study: 6176322

Group type: EXPERIMENTAL
Intervention: MOPP-ABVD and irradiation
Number of subjects: 155

Group type: COMPARATOR
Intervention: MVVPP
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Combined modality therapy
Number of subjects: 155
Study: 31211448

Group type: EXPERIMENTAL
Intervention: BIIB054 (15 or 45 mg/kg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: BIIB054 (1-135 mg/kg)
Number of subjects: 66
Study: 27324516

Group type: EXPERIMENTAL
Intervention: Elemental diet (ED) from the day prior to surgery until postoperative day (POD) 3
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional perioperative diet program
Number of subjects: 94
Study: 24676715

Group type: EXPERIMENTAL
Intervention: Polypill-based strategy (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, and either atenolol 50mg or hydrochlorothiazide 12.5mg)
Number of subjects: 623

Group type: COMPARATOR
Intervention: Usual care (separate medications and doses as prescribed by their doctor)
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Polypill-based strategy
Number of subjects: 623
Study: 23073367

Group type: EXPERIMENTAL
Intervention: Meaning-focused interventions (dialogic reading or shared reading)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Code-focused interventions (phonological awareness, letter knowledge, or both)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Combined phonological awareness and letter knowledge interventions
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 324
Study: 22133251

Group type: EXPERIMENTAL
Intervention: Moderate-intensity intradialytic aerobic training program 3 times per week for 12 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-intensity constant work rate (CWR) test
Number of subjects: 28

Group type: COMPARATOR
Intervention: Incremental work rate (IWR) test
Number of subjects: 28
Study: 18985382

Group type: EXPERIMENTAL
Intervention: Hand position during sequence learning in Experiment 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Executing entire sequences by reacting to one cue in Experiment 2
Number of subjects: 0
Study: 16143492

Group type: EXPERIMENTAL
Intervention: ImPACT Test Battery
Number of subjects: 72
Study: 13678427

Group type: EXPERIMENTAL
Intervention: Irbesartan (angiotensin II type I receptor antagonist)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Atenolol (beta1‐adrenoceptor blocker)
Number of subjects: 90
Study: 11045833

Group type: EXPERIMENTAL
Intervention: Use of antacid and anti-ulcer drugs during the last month of pregnancy by mothers
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Cardiac deceleration during labor and delivery
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Breast-feeding at birth
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Mean state anxiety score of mothers
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Mean trait anxiety scores of mothers
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Use of antacid and anti-ulcer treatments
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Cardiac deceleration
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 137
Study: 8884843

Group type: EXPERIMENTAL
Intervention: Vitamin E (600 mg/day) for 28 days, vitamin C (2 g/day), and allopurinol (600 mg/day) for 2 days before and 1 day after CABG (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: All drugs for 3 days (Group C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Corresponding controls (Group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Corresponding controls (Group D)
Number of subjects: 20
Study: 1533528

Group type: EXPERIMENTAL
Intervention: 1.25 mg isradipine twice daily
Number of subjects: 174

Group type: COMPARATOR
Intervention: 40 mg diltiazem thrice daily
Number of subjects: 174
Study: 6691394

Group type: EXPERIMENTAL
Intervention: Betamethasone (12 mg)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (250 mg)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (125 mg)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study: 31383509

Group type: EXPERIMENTAL
Intervention: Renal artery embolization (RAE)
Number of subjects: 15
Study: 29436324

Group type: EXPERIMENTAL
Intervention: Immediate access to low-intensity CBT intervention
Number of subjects: 142

Group type: COMPARATOR
Intervention: Delayed access to low-intensity CBT intervention
Number of subjects: 142
Study: 26982815

Group type: EXPERIMENTAL
Intervention: Tirasemtiv (125 mg b.i.d. for one week, then escalating to a maximum tolerated dose up to 250 mg b.i.d.)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Tirasemtiv
Number of subjects: 596
Study: 24786192

Group type: EXPERIMENTAL
Intervention: Topical formulation with high water activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical formulation with urea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical formulation with glycerol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical formulation with low water activity
Number of subjects: 0
Study: 21904296

Group type: EXPERIMENTAL
Intervention: Initiation of milk expression within 60 min after delivery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Initiation of milk expression between 1 to 6 hours after delivery
Number of subjects: 20
Study: 21194471

Group type: EXPERIMENTAL
Intervention: High protein meal replacement (HP) providing 2.2 g protein/kg of lean body mass (LBM)/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard protein meal replacement (SP) providing 1.1 g protein/kg LBM/day
Number of subjects: 100
Study: 17478542

Group type: EXPERIMENTAL
Intervention: Indian HB vaccine (GeneVac‐B)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: European HB vaccine (Engerix‐B)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Both vaccines
Number of subjects: 262
Study: 15630104

Group type: EXPERIMENTAL
Intervention: Self-management group (n = 368)
Number of subjects: 737

Group type: COMPARATOR
Intervention: Conventional management group (n = 369)
Number of subjects: 737
Study: 11336429

Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 1821

Group type: COMPARATOR
Intervention: Nova-T
Number of subjects: 1821
Study: 12596840

Group type: EXPERIMENTAL
Intervention: Self-help module
Number of subjects: 98

Group type: COMPARATOR
Intervention: Routine counseling
Number of subjects: 98
Study: 8155448

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2844467

Group type: EXPERIMENTAL
Intervention: S‐9780 (1 mg administered intravenously)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg administered orally)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Adverse effects (mild headache and light-headedness)
Number of subjects: 16
Study: 29360570

Group type: EXPERIMENTAL
Intervention: Psychological stress
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor‐α
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Stress and tumor necrosis factor‐α
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 158
Study: 28049491

Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg per day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 25744873

Group type: EXPERIMENTAL
Intervention: Menthol smokers
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Menthol smokers with higher levels of dependence
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: FTND
Number of subjects: 186
Study: 23053692

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention with aftercare (MD)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Aerobic exercise (AE)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 203
Study: 21177013

Group type: EXPERIMENTAL
Intervention: Tacrolimus (n = 42)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (n = 39)
Number of subjects: 81
Study: 18326602

Group type: EXPERIMENTAL
Intervention: CARB-B (breakfast intervention)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CARB-L (lunch intervention)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CARB-D (dinner intervention)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CARB-E (even distribution intervention)
Number of subjects: 23
Study: 16549962

Group type: EXPERIMENTAL
Intervention: Lamivudine monotherapy (300 mg once daily)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Complete therapy interruption (TI group)
Number of subjects: 58
Study: 12665739

Group type: EXPERIMENTAL
Intervention: Handwashing
Number of subjects: 224
Study: 10561655

Group type: EXPERIMENTAL
Intervention: Computerized interpretation of nonstress test results
Number of subjects: 404

Group type: COMPARATOR
Intervention: Visual interpretation of nonstress test results
Number of subjects: 404
Study: 8730978

Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1872132

Group type: EXPERIMENTAL
Intervention: 1% Indometacin
Number of subjects: 49

Group type: COMPARATOR
Intervention: 0.1% Dexametason
Number of subjects: 49
Study: 6866594

Group type: EXPERIMENTAL
Intervention: Experimental group (demonstration of the Brazelton Neonatal Assessment Scale)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control groups (two control groups)
Number of subjects: 75
Study: 29121408

Group type: EXPERIMENTAL
Intervention: CHW support
Number of subjects: 244

Group type: COMPARATOR
Intervention: No CHW support
Number of subjects: 244
Study: 25971439

Group type: EXPERIMENTAL
Intervention: Highest quartile of 25(OH)D
Number of subjects: 1340

Group type: EXPERIMENTAL
Intervention: Highest quartile of FGF23
Number of subjects: 1340
Study: 24292412

Group type: EXPERIMENTAL
Intervention: Psychoeducation programme
Number of subjects: 81

Group type: COMPARATOR
Intervention: Parent counselling and support intervention
Number of subjects: 81
Study: 22250997

Group type: EXPERIMENTAL
Intervention: Early childhood education treatment
Number of subjects: 101
Study: 20732609

Group type: EXPERIMENTAL
Intervention: Serious game training
Number of subjects: 91

Group type: COMPARATOR
Intervention: Card-sort exercise
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 91
Study: 18294750

Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide (bleaching group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saliva (control group)
Number of subjects: 36
Study: 15923508

Group type: EXPERIMENTAL
Intervention: Retrobulbar anaesthesia
Number of subjects: 39

Group type: COMPARATOR
Intervention: Subconjunctival anaesthesia
Number of subjects: 39
Study: 12888049

Group type: COMPARATOR
Intervention: Normal room air breathing
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Isoxic hypercapnia
Number of subjects: 22
Study: 10619580

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 268

Group type: COMPARATOR
Intervention: Losartan 50 mg
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg vs 16 mg
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 268
Study: 7568642

Group type: EXPERIMENTAL
Intervention: Vaginal pulse amplitude
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaginal blood volume
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin conductance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjective sexual arousal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body sensations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional experience
Number of subjects: 0
Study: 1777373

Group type: EXPERIMENTAL
Intervention: Intravenous administration of dermatan sulphate (200 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of dermatan sulphate (100 and 300 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral administration of dermatan sulphate (1 g)
Number of subjects: 12
Study: 7028071

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate preceded 10 minutes earlier by inhalation of salbutamol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Inhaled beclomethasone dipropionate followed 10 minutes later by salbutamol
Number of subjects: 60
Study: 6490470

Group type: EXPERIMENTAL
Intervention: Tap water (n = 8)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Iodine-treated tap water (n = 11)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Iodine-treated flavored tap water (n = 10)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Warm drinks
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cool drinks
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Warm iodine-treated water
Number of subjects: 29
Study: 28661984

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Burned children
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonburned children
Number of subjects: 20
Study: 28054924

Group type: EXPERIMENTAL
Intervention: Braden Scale assessment by nurses and research staff
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Qualitative survey of nurses' perspectives
Number of subjects: 64
Study: 24738161

Group type: EXPERIMENTAL
Intervention: Pivmecillinam (PIV)
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1143
Study: 22410469

Group type: EXPERIMENTAL
Intervention: Right lateral position for 6 min before assuming wedged supine position (group L)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Wedge supine position immediately after spinal injection (group S)
Number of subjects: 86
Study: 20488453

Group type: EXPERIMENTAL
Intervention: Selective head cooling
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control (rectal temperature maintained at 36.0 to 37.5 degrees C)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control
Number of subjects: 194
Study: 18367694

Group type: EXPERIMENTAL
Intervention: Word-based training
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sentence-based training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Phoneme-based training
Number of subjects: 18
Study: 16315159

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 12432412

Group type: EXPERIMENTAL
Intervention: FOCUS Program (family involvement, optimistic attitude, coping effectiveness, uncertainty reduction, and symptom management) delivered in three home visits and two follow-up phone calls over a five-month period.
Number of subjects: 0
Study: 10487480

Group type: EXPERIMENTAL
Intervention: Autologous LDL
Number of subjects: 49

Group type: COMPARATOR
Intervention: Homologous LDL
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: XbaI -/- genotype
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: EcoRI +/+ genotype
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: apo E 4 genotype
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: apo B polymorphisms
Number of subjects: 49
Study: 8594280

Group type: EXPERIMENTAL
Intervention: Posture Training Support (PTS)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Conventional thoracolumbar support
Number of subjects: 45

Group type: COMPARATOR
Intervention: Postural exercise only (Control)
Number of subjects: 45
Study: 1673123

Group type: EXPERIMENTAL
Intervention: Intramuscular lorazepam 2 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular haloperidol 5 mg
Number of subjects: 0
Study: 6754416

Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray (200 micrograms and 400 micrograms per day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray (long-term use for more than two years)
Number of subjects: 36